Half-year report · Q2
6856.TEDINET S100U74Z
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥142.7bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥290.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥131.1bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Operating income | ¥18.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | ¥17.8bn | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | ¥19.3bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥48.3bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.1bn | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥19.2bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥24.4bn | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | ¥19.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥469.3bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥449.0bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥435.3bn | at 2023-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥165.6bn | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥165.3bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥303.8bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥283.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥266.8bn | at 2023-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥134.4bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥132.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥134.2bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥130.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥127.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥138.8bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.4bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.3bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥9.7bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.0bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥18.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥312.43 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥953.71 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥449.87 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥310.83 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥948.83 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥447.66 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 64.6% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥38.6bn |
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥38.6bn |
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥1.2bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥16.4bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥16.4bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥456m |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥11.7bn |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥162m |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥18.8bn |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥18.8bn |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥174m |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥57.3bn |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥57.3bn |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥20.3bn |
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥30.5bn |
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥30.5bn |
| jpcrp040300-q2r_E01901-000Automotive Test Systemsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥2.2bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥15.6bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥15.6bn |
| jpcrp040300-q2r_E01901-000Medical Diagnostic Instruments And Systemsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥178m |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥11.3bn |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥11.3bn |
| jpcrp040300-q2r_E01901-000Process And Environmental Instruments And Systemsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥916m |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E01901-000Scientific Instruments And Systemsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥213m |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥56.2bn |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥56.2bn |
| jpcrp040300-q2r_E01901-000Semiconductor Instruments And Systemsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥18.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 557
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | 30545000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | 11336000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | 15592000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | 56225000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | 17404000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 131105000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | -2159000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | 916000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | 178000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | 18689000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | 213000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 17838000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | 38620000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | 11709000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | 16350000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | 57256000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | 18783000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 142720000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | 38620000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | 11709000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | 16350000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | 57256000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | 18783000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 142720000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E01901-000AutomotiveTestSystemsReportableSegmentMember | -1169000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ProcessAndEnvironmentalInstrumentsAndSystemsReportableSegmentMember | 162000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E01901-000MedicalDiagnosticInstrumentsAndSystemsReportableSegmentMember | -456000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E01901-000SemiconductorInstrumentsAndSystemsReportableSegmentMember | 20254000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E01901-000ScientificInstrumentsAndSystemsReportableSegmentMember | -174000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 18615000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |